Table 3 Clinical results at 5 years
|  | Sirolimus- and probucol-eluting stent (n = 575) | Zotarolimus-eluting stent (n = 295) | Hazard ratio [95 % CI] | P value |
|---|---|---|---|---|
Cardiac death, target vessel-related myocardial infarction or target lesion revascularization | 178 (32.9) | 91 (33.4) | 0.98 [0.76–1.26] | 0.88 |
Cardiac death or target vessel-related myocardial infarction | 101 (19.1) | 54 (20.1) | 0.94 [0.67–1.30] | 0.70 |
Cardiac death | 81 (15.6) | 44 (16.7) | 0.92 [0.63–1.32] | 0.64 |
Target vessel-related myocardial infarction | 26 (4.6) | 18 (6.6) | 0.73 [0.40–1.34] | 0.31 |
Target lesion revascularization | 100 (18.6) | 50 (18.8) | 1.00 [0.72–1.41] | 0.98 |
All-cause death | 133 (24.4) | 79 (27.8) | 0.84 [0.63–1.11] | 0.21 |
Any myocardial infarction | 37 (6.5) | 21 (7.6) | 0.90 [0.53–1.54] | 0.70 |
Any revascularization | 234 (43.4) | 124 (46.9) | 0.92 [0.74–1.15] | 0.48 |
Target vessel revascularization | 144 (26.8) | 70 (26.2) | 0.82 [0.78–1.37] | 0.82 |
Definite or probable stent thrombosis | 14 (2.5) | 7 (2.6) | 1.02 [0.41–2.52] | 0.97 |
Definite stent thrombosis | 7 (1.2) | 4 (1.6) | 0.89 [0.26–3.04] | 0.85 |
Probable stent thrombosis | 7 (1.2) | 3 (1.0) | 1.19 [0.31–4.60] | 0.80 |